This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Stemline Therapeutics Reports Year-End 2012 Financial Results


Selected Financial Data (In Thousands, Except Share and Per Share Amounts)
  Year ended December 31,
  2011 2012
Operating expenses:    
Research and development $1,629 $3,377
General and administrative 1,088 3,091
Total operating expenses 2,717 6,468
Loss from operations (2,717) (6,468)
Other income 47 302
Other expense (10) --  
Interest expense (99) (119)
Interest income 24 10
Net income (loss) attributable to common stockholders $(2,755) $(6,275)
Net income (loss) attributable to common stockholders per common share:    
Basic $(.80) $(1.82)
Diluted $(.80) $(1.82)
Weighted‑average shares outstanding:    
Basic and diluted 3,441,995 3,441,995


  December 31,
  2011 2012
Balance sheet data:    
Cash and cash equivalents $5,830 $2,025
Total assets $6,453 $5,030
Long-term liabilities $1,665 $2,037
(Deficit)/earnings accumulated during development stage $(894) $(7,169)
Total stockholders' (deficit)/equity $3,205 $(2,508)
CONTACT: Mark Jacobson
         Director, Corporate Development
         Stemline Therapeutics, Inc.
         750 Lexington Avenue
         Sixth Floor
         New York, NY 10022
         Tel: 646-502-2307

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.30 1.80%
FB $117.72 -0.72%
GOOG $696.03 -0.31%
TSLA $233.19 -3.60%
YHOO $36.10 -1.20%


Chart of I:DJI
DOW 17,769.98 -121.18 -0.68%
S&P 500 2,064.04 -17.39 -0.84%
NASDAQ 4,773.0850 -44.5090 -0.92%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs